Acid-base and electrolyte disorders associated with the use of antidiabetic drugs

Expert Opinion on Drug Safety

Volumn 16, Issue 10, 2017, Pages 1121-1132

  Filippatos, Theodosios ^a   Tzavella, Eleftheria ^a   Rizos, Christos ^a   Elisaf, Moses ^a   Liamis, George ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

diabetic ketoacidosis; electrolytes; insulin; lactic acidosis; magnesium; metformin; phosphorus; pioglitazone; potassium; SGLT2 inhibitors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ELECTROLYTE; INSULIN; MAGNESIUM; METFORMIN; PHOSPHORUS; PIOGLITAZONE; POTASSIUM; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2;

DIABETIC KETOACIDOSIS; DISORDERS OF ACID BASE BALANCE; DRUG EFFECT; ELECTROLYTE DISTURBANCE; HUMAN; LACTIC ACIDOSIS; MAGNESIUM BLOOD LEVEL; MAGNESIUM EXCRETION; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; REVIEW; URINARY EXCRETION; ACID BASE BALANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLIC DISORDER; RISK FACTOR;

ACID-BASE EQUILIBRIUM; ACID-BASE IMBALANCE; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINEDIONES; WATER-ELECTROLYTE IMBALANCE;

EID: 85029522523     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1361400     Document Type: Review

References (150)

1. American Diabetes Association. Standards of medical care in diabetes - 2017. Diabetes Care. 2017;40(Suppl 1):S1–135.
2. Agouridis AP, Rizos CV, Elisaf MS, et al. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud. 2013;10:171–190.
3. Filippatos TD, Elisaf MS., Combination drug treatment in obese diabetic patients. World J Diabetes. 2010;1:8–11.
4. Opie LH., Sodium glucose co-transporter 2 (SGLT2) inhibitors:new among antidiabetic drugs. Cardiovasc Drugs Ther. 2014;28:331–334.
5. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des. 2010;16:3401–3416.
6. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs. 2008;17:1599–1614.
7. Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945–1958.
8. Filippatos TD, Elisaf MS. Pitavastatin and carbohydrate metabolism:what is the evidence? Expert Rev Clin Pharmacol. 2016;9:955–960.
9. Filippatos TD, Elisaf MS. Statin-ezetimibe combination therapy in diabetic individuals. Angiology. 2016;67:507–509.
10. Filippatos TD, Florentin M, Georgoula M, et al. Pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2017;10:187–200.
11. Filippatos TD, Elisaf MS. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14:1481–1493.
12. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.•• An important study that showed cardiovascular benefits with empagliflozin treatment.
13. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
14. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
15. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
16. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
17. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
18. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
19. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
20. Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opin Pharmacother. 2016;17:1581–1583.
21. Tsimihodimos V, Filippatos TD, Elisaf MS. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism:unanswered questions and controversies. Expert Opin Drug Metab Toxicol. 2016;13:1–10.
22. Filippatos TD, Athyros VG, Elisaf MS. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors. Expert Opin Drug Metab Toxicol. 2014;10:787–812.
23. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11:202–230.
24. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52:144–153.
25. Liamis G, Filippatos TD, Elisaf MS. Thiazide-associated hyponatremia in the elderly:what the clinician needs to know. J Geriatr Cardiol. 2016;13:175–182.
26. Visconti L, Cernaro V, Ferrara D, et al. Metformin-related lactic acidosis:is it a myth or an underestimated reality? Ren Fail. 2016;38:1560–1565.
27. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81–98.
28. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
29. Ravindran S, Kuruvilla V, Wilbur K, et al. Nephroprotective effects of metformin in diabetic nephropathy. J Cell Physiol. 2017;232:731–742.
30. Klachko D, Whaley-Connell A. Use of metformin in patients with kidney and cardiovascular diseases. Cardiorenal Med. 2011;1:87–95.
31. Kooy A, De Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616–625.
32. National Institute for Health and Clinical Excellence. Type 2 diabetes:the management of type 2 diabetes. NG28. cited 2017 Jan 30. Available from: https://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations-blood-glucose-management-2.
33. Moioli A, Maresca B, Manzione A, et al. Metformin associated lactic acidosis (MALA):clinical profiling and management. J Nephrol. 2016;29:783–789.
34. Chowdhury TA, Srirathan D, Abraham G, et al. Could metformin be used in patients with diabetes and advanced chronic kidney disease? Diabetes Obes Metab. 2017;19:156–161.
35. Lalau JD. Lactic acidosis induced by metformin:incidence, management and prevention. Drug Saf. 2010;33:727–740.
36. Lalau JD, Kajbaf F, Protti A, et al. Metformin-associated lactic acidosis (MALA):moving towards a new paradigm. Diabetes Obes Metab. 2017. Epub ahead of print. Doi:10.1111/dom.12974
37. Bicsak TA, Walsh B, Fineman M. Metformin-associated lactic acidosis (MALA):moving towards a new paradigm? Diabetes Obes Metab. 2017. Epub ahead of print. Doi:10.1111/dom.12994.
38. Eppenga WL, Lalmohamed A, Geerts AF, et al. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment:a population-based cohort study. Diabetes Care. 2014;37:2218–2224.
39. Richy FF, Sabido-Espin M, Guedes S, et al. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin:a retrospective cohort study. Diabetes Care. 2014;37:2291–2295.
40. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;CD002967.
41. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care. 1995;18:779–784.
42. Vecchio S, Giampreti A, Petrolini VM, et al. Metformin accumulation:lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol (Phila). 2014;52:129–135.
43. Stades AM, Heikens JT, Erkelens DW, et al. Metformin and lactic acidosis:cause or coincidence? A review of case reports. J Intern Med. 2004;255:179–187.
44. Connelly PJ, Lonergan M, Soto-Pedre E, et al. Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users:A GoDarts study. Diabetes Obes Metab. 2017. Epub ahead of print. doi:10.1111/dom.12978• An interesting study examining precipitating factors of lactic acidosis in metformin users.
45. Rocha A, Almeida M, Santos J, et al. Metformin in patients with chronic kidney disease:strengths and weaknesses. J Nephrol. 2013;26:55–60.
46. Spiller HA, Quadrani DA. Toxic effects from metformin exposure. Ann Pharmacother. 2004;38:776–780.
47. Al-Abri SA, Hayashi S, Thoren KL, et al. Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs. Clin Toxicol (Phila). 2013;51:444–447.
48. Perrone J, Phillips C, Gaieski D. Occult metformin toxicity in three patients with profound lactic acidosis. J Emerg Med. 2011;40:271–275.
49. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–1174.
50. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin:an overview. Clin Sci (Lond). 2012;122:253–270.
51. Protti A, Lecchi A, Fortunato F, et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care. 2012;16:R180.
52. Bando K, Ochiai S, Kunimatsu T, et al. Comparison of potential risks of lactic acidosis induction by biguanides in rats. Regul Toxicol Pharmacol. 2010;58:155–160.
53. Semely D, Bennett E, Vallejo C, et al. Can an early diagnostic procedure of metformin-associated lactic acidosis in an emergency unit reduce mortality? Therapie. 2016;71:605–612.
54. Lalau JD, Lacroix C. Measurement of metformin concentration in erythrocytes:clinical implications. Diabetes Obes Metab. 2003;5:93–98.
55. Pan LT, MacLaren G. Continuous venovenous haemodiafiltration for metformin-induced lactic acidosis. Anaesth Intensive Care. 2009;37:830–832.
56. Liamis G, Milionis HJ, Elisaf M. Pharmacologically-induced metabolic acidosis:a review. Drug Saf. 2010;33:371–391.
57. Liamis G, Liberopoulos E, Alexandridis G, et al. Hypomagnesemia in a department of internal medicine. Magnes Res. 2012;25:149–158.
58. Liamis G, Liberopoulos E, Barkas F, et al. Diabetes mellitus and electrolyte disorders. World J Clin Cases. 2014;2:488–496.
59. Liamis G, Rodenburg EM, Hofman A, et al. Electrolyte disorders in community subjects:prevalence and risk factors. Am J Med. 2013;126:256–263.
60. Peters KE, Chubb SA, Davis WA, et al. The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes:the Fremantle Diabetes Study. PLoS One. 2013;8:e74355.
61. Kurstjens S, De Baaij JH, Bouras H, et al. Determinants of hypomagnesemia in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2017;176:11–19.
62. McBain AM, Brown IR, Menzies DG, et al. Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes. J Clin Pathol. 1988;41:933–935.
63. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract. 2011;93:56–62.
64. Svare A. A patient presenting with symptomatic hypomagnesemia caused by metformin-induced diarrhoea:a case report. Cases J. 2009;2:156.
65. Dosa MD, Hangan LT, Crauciuc E, et al. Influence of therapy with metformin on the concentration of certain divalent cations in patients with non-insulin-dependent diabetes mellitus. Biol Trace Elem Res. 2011;142:36–46.
66. Gorelik O, Efrati S, Berman S, et al. Effect of various clinical variables on total intracellular magnesium in hospitalized normomagnesemic diabetic patients before discharge. Biol Trace Elem Res. 2007;120:102–109.
67. Alon I, Berman S, Shteinshnaider M, et al. Total cellular calcium and magnesium content of cultured human peripheral blood mononuclear cells following exposure to antidiabetic drugs. Acta Diabetol. 2006;43:46–51.
68. Ewis SA, Abdel-Rahman MS. Effect of metformin on glutathione and magnesium in normal and streptozotocin-induced diabetic rats. J Appl Toxicol. 1995;15:387–390.
69. Niranjan G, Mohanavalli V, Srinivasan AR, et al. Serum lipid peroxides and magnesium levels following three months of treatment with pioglitazone in patients with type-2 diabetes mellitus. Diabetes Metab Syndr. 2013;7:35–37.
70. Guerrero-Romero F, Rodriguez-Moran M. Pioglitazone increases serum magnesium levels in glucose-intolerant subjects. A randomized, controlled trial. Exp Clin Endocrinol Diabetes. 2003;111:91–96.• An interesting study that examined the effects of pioglitazone on magnesium levels.
71. Nadler J, Scott S. Evidence that pioglitazone increases intracellular free magnesium concentration in freshly isolated rat adipocytes. Biochem Biophys Res Commun. 1994;202:416–421.
72. Da Silva CA, De Braganca AC, Shimizu MH, et al. Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression. Am J Physiol Renal Physiol. 2009;297:F916–F922.
73. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in adult patients with diabetes:a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29:2739–2748.
74. Wang ZH, Kihl-Selstam E, Eriksson JW. Ketoacidosis occurs in both type 1 and type 2 diabetes–a population-based study from northern Sweden. Diabet Med. 2008;25:867–870.
75. Chiasson JL, Aris-Jilwan N, Belanger R, et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Cmaj. 2003;168:859–866.
76. Yanai H, Katsuyama H, Hamasaki H, et al. Sodium-glucose cotransporter 2 inhibitors:possible anti-atherosclerotic effects beyond glucose lowering. J Clin Med Res. 2016;8:10–14.
77. Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors:basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017. Epub ahead of print. Doi:10.1002/dmrr.2886• An interesting manuscript that examined the mechanisms associated with the SGLT2 inhibitors-induced diabetic ketoacidosis.
78. Laffel L. Ketone bodies:a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15:412–426.
79. Fukao T, Mitchell G, Sass JO, et al. Ketone body metabolism and its defects. J Inherit Metab Dis. 2014;37:541–551.
80. Turner J, Begum T, Smalligan RD. Canagliflozin-induced diabetic ketoacidosis:case report and review of the literature. J Investig Med High Impact Case Rep. 2016;4:2324709616663231.
81. Clement M, Senior P. Euglycemic diabetic ketoacidosis with canagliflozin:not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use. Can Fam Physician. 2016;62:725–728.
82. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
83. Kalra S, Sahay R, Gupta Y. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab. 2015;19:524–528.
84. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis:a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642.
85. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis:a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–1693.
86. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig. 2015;6:587–590.
87. Bloomgarden ZT. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis. J Diabetes. 2016;8:175–176.
88. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. 2015 [cited 2017 Jan 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/Procedure_started/WC500187926.pdf.
89. U.S. Food and Drug Administration 2015. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. [cited 2017 Jan 21]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf.
90. Goldenberg RM, Berard LD, Cheng AY, et al. SGLT2 inhibitor-associated diabetic ketoacidosis:clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38:2654–2664 e1.
91. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680–1686.
92. Lund S, Solimando F, Kohler S. Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM):pooled clinical trial data. Diabetologia. 2016;59(Suppl. 1):S26–S7abstract 50. Available from:http://doi.org/10.1007/s00125-016-4046-9
93. Tang H, Li D, Wang T, et al. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes:a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39:e123–e124.
94. West K, WEebb L, Fenech M, et al. Possible risk factors for the development of sodium-glucose co-transporter 2 inhibitor- associated diabetic ketoacidosis in type 2 diabetes. Br J Diabetes. 2016;16:78–81.
95. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309:F889–F900.
96. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
97. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514.
98. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
99. Palmer BF, Clegg DJ, Taylor SI, et al. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complications. 2016;30:1162–1166.
100. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes:a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17:928–935.
101. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–1195.
102. Yabe D, Iwasaki M, Kuwata H, et al. SGLT2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes:a randomized, open-label, 3-arm parallel comparative exploratory study. Diabetes Obes Metab. 2016;19:739–743.
103. Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk:lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717–725.
104. Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37:3192–3200.
105. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial:A “thrifty substrate” hypothesis. Diabetes Care. 2016;39:1108–1114.
106. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
107. Tsimihodimos V, Filippatos TD, Fillippas-Ntekouan S, et al. Renoprotective effects of SGLT2 inhibitors:beyond glucose reabsorption inhibition. Curr Vasc Pharmacol. 2016;15:96–102.
108. Tang H, Zhang X, Zhang J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients:a meta-analysis of randomised controlled trials. Diabetologia. 2016;59:2546–2551.• A meta-analysis which showed that SGLT2 inhibitors induce an increase in serum magnesium concentration.
109. Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016–1027.
110. Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30:1759–1768.
111. Kimura G. Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes:pathophysiological hypothesis. J Am Soc Hypertens. 2016;10:271–278.
112. Yavin Y, Mansfield TA, Ptaszynska A, et al. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus:a pooled analysis. Diabetes Ther. 2016;7:125–137.
113. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
114. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.
115. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44–51.
116. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157–166.
117. Alba M, Xie J, Fung A, et al. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1375–1385.
118. Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990–999.
119. Egger A, Kraenzlin ME, Meier C. Effects of incretin-based therapies and SGLT2 inhibitors on skeletal health. Curr Osteoporos Rep. 2016;14:345–350.
120. Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients:a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18:1199–1206.
121. Minaker KL, Rowe JW. Potassium homeostasis during hyperinsulinemia:effect of insulin level, beta-blockade, and age. Am J Physiol. 1982;242:E373–E377.
122. Kamel KS, Schreiber M, Carlotti AP, et al. Approach to the treatment of diabetic ketoacidosis. Am J Kidney Dis. 2016;68:967–972.
123. Wu D, Kraut JA. Role of NHE1 in the cellular dysfunction of acute metabolic acidosis. Am J Nephrol. 2014;40:36–42.
124. Van der Meulen JA, Klip A, Grinstein S. Possible mechanism for cerebral oedema in diabetic ketoacidosis. Lancet. 1987;2:306–308.
125. Petersen KG, Schlüter KJ, Kerp L. Regulation of serum potassium during insulin-induced hypoglycemia. Diabetes. 1982;31:615–617.
126. Carlotti AP, St George-Hyslop C, Bohn D, et al. Hypokalemia during treatment of diabetic ketoacidosis:clinical evidence for an aldosterone-like action of insulin. J Pediatr. 2013;163:207–212 e1.
127. Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int. 1989;35:1–13.
128. Murthy K, Harrington JT, Siegel RD. Profound hypokalemia in diabetic ketoacidosis:a therapeutic challenge. Endocr Pract. 2005;11:331–334.
129. Arora S, Cheng D, Wyler B, et al. Prevalence of hypokalemia in ED patients with diabetic ketoacidosis. Am J Emerg Med. 2012;30:481–484.
130. Kanwal SK, Bando A, Kumar V. Clinical profile of diabetic ketoacidosis in Indian children. Indian J Pediatr. 2012;79:901–904.
131. Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes. 2014;7:255–264.
132. Liamis G, Liberopoulos E, Barkas F, et al. Spurious electrolyte disorders:a diagnostic challenge for clinicians. Am J Nephrol. 2013;38:50–57.
133. Matsumura M, Nakashima A, Tofuku Y. Electrolyte disorders following massive insulin overdose in a patient with type 2 diabetes. Intern Med. 2000;39:55–57.
134. Paolisso G, Sgambato S, Passariello N, et al. Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia. 1986;29:644–647.
135. Xu LH, Maalouf NM. Effect of acute hyperinsulinemia on magnesium homeostasis in humans. Diabetes Metab Res Rev. 2017;33(2). doi:10.1002/dmrr.2844.
136. Nair AV, Hocher B, Verkaart S, et al. Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Natl Acad Sci U S A. 2012;109:11324–11329.
137. Takayanagi K, Shimizu T, Tayama Y, et al. Downregulation of transient receptor potential M6 channels as a cause of hypermagnesiuric hypomagnesemia in obese type 2 diabetic rats. Am J Physiol Renal Physiol. 2015;308:F1386–F1397.
138. Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia:a review. Qjm. 2010;103:449–459.
139. Kebler R, McDonald FD, Cadnapaphornchai P. Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med. 1985;79:571–576.
140. Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis. 2012;60:655–661.
141. Beukhof CM, Hoorn EJ, Lindemans J, et al. Novel risk factors for hospital-acquired hyponatraemia:a matched case-control study. Clin Endocrinol (Oxf). 2007;66:367–372.
142. Bustamante M, Hasler U, Kotova O, et al. Insulin potentiates AVP-induced AQP2 expression in cultured renal collecting duct principal cells. Am J Physiol Renal Physiol. 2005;288:F334–F344.
143. Liamis G, Milionis H, Elisaf M. Blood pressure drug therapy and electrolyte disturbances. Int J Clin Pract. 2008;62:1572–1580.
144. Filippatos TD, Elisaf MS. Hyponatremia in patients with heart failure. World J Cardiol. 2013;5:317–328.
145. Filippatos TD, Liamis G, Christopoulou F, et al. Ten common pitfalls in the evaluation of patients with hyponatremia. Eur J Intern Med. 2016;29:22–25.
146. Filippatos TD, Liamis G, Elisaf MS. Ten pitfalls in the proper management of patients with hyponatremia. Postgrad Med. 2016;128:516–522.
147. Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol. 2016;777:78–87.
148. Liamis G, Filippatos TD, Liontos A, et al. Hyponatremia in patients with liver diseases:not just a cirrhosis-induced hemodynamic compromise. Hepatol Int. 2016;10:762–772.
149. Liamis G, Filippatos TD, Liontos A, et al. Management of endocrine disease:hypothyroidism-associated hyponatremia:mechanisms, implications and treatment. Eur J Endocrinol. 2017;176:R15–R20.
150. Liamis G, Milionis HJ, Elisaf M. Hyponatremia in patients with infectious diseases. J Infect. 2011;63:327–335.